Experiments were designed to determine the effects of supplemental dietary l-arginine on the endothelial and smooth muscle function of canine coronary arteries. One group of dogs was fed the standard laboratory chow while another group was supplemented with 250 mg/kg per day l-arginine. All dogs had undergone bilateral reversed interposition saphenous vein grafting and received 325 mg/day oral aspirin. After 5 weeks of arginine feeding, left circumflex coronary arteries were removed, cut into rings, and suspended for the measurement of isometric force in organ chambers. Concentration-response curves were obtained to l-arginine, UK-14,304 (␣ 2 -adrenergic agonist) and A23187 (calcium ionophore) in the absence and presence of N G -monomethyl-l-arginine (l-NMMA) and tetraethylammonium (TEA) alone or in combination.
Introduction
Nitric oxide is synthesized in the vasculature from l-arginine by nitric oxide synthases (NOS). 1 In addition to causing relaxation of both arterial and venous smooth muscle cells, nitric oxide also inhibits their proliferation. [2] [3] [4] It has been hypothesized, therefore, that increasing the bioavailability of nitric oxide, perhaps by increasing substrate, may reduce development of occlusive vascular disease such as atherosclerosis or neointimal formation following arterial injury or vascular grafts. Indeed, dietary supplementation with l-arginine inhibits development of atherosclerosis, decreases monocyte adhesiveness, and reduces intimal hyperplasia in vein grafts in experimental animals and humans with hypercholesterolemia. [5] [6] [7] [8] [9] Dietary supplemental l-arginine may also decrease platelet reactivity thereby reducing the release of promitogenic platelet-derived factors at the site of vascular injury. [10] [11] [12] Effects of l-arginine may be related to the existence of hypercholesterolemia, duration of treatment, and coexisting vascular conditions such as atherosclerosis, heart failure, or vascular injury. [13] [14] [15] [16] Under these conditions, where nitric oxide from type II NOS (inducible) is prominent, 17 or circulating concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) are high, 9 dietary supplementation with l-arginine may be beneficial. However, under conditions of unstimulated or basal nitric oxide production in the absence of cardiovascular disease, vascular effects of l-arginine dietary supplementation may not be observed. 18 In addition to being metabolized by nitric oxide synthase, l-arginine may also be metabolized by arginine decarboxylase to agmatine which acts as an endogenous ␣ 2 -adrenergic receptor agonist, and inhibitor of nitric oxide synthase, [19] [20] [21] and by arginase to ornithine which can then lead to production of polyamines. [22] [23] [24] Also, l-arginine may bind to an ATP-sensitive potassium channel affecting changes in vascular reactivity independent of formation of nitric oxide and subsequent activation of soluble guanylate cyclase. 25 Given that there are multiple metabolic portions for arginine and that arginine dietary supplements are available commercially, it is important to define the effects of arginine supplementation in the absence of disease processes. Experiments in the present study, therefore, were designed to determine the effects of dietary arginine on the function of endothelium and smooth muscle cells in canine coronary arteries in the absence of hypercholesterolemia, atherosclerosis, or active vascular remodeling. The hypothesis tested was that dietary supplementation with arginine would increase endothelium-dependent relaxations in coronary arteries free of pre-existing disease or injury.
Materials and methods

Experimental animals
Male mongrel dogs (weight 25 kg) were anesthetized (sodium pentobarbital 30 mg/kg, intravenous) and underwent bilateral autogenous reversed saphenous vein grafts interposed into femoral arteries. Each dog received prophylactic antibiotics preoperatively (penicillin G, 1 million units; gentamycin sulfate, 80 mg intramuscularly). Eight dogs received oral supplemental l-arginine (argininefed; 250 mg/kg per day mixed with canned dog food) starting 1 week prior to surgery, and continuing for 4 weeks. Ten dogs (control) underwent the grafting procedure but did not receive l-arginine supplementation. All animals received aspirin (325 mg/day, orally) postoperatively. Plasma concentrations of l-arginine, proline, ornithine and citrulline, and oxidized products of nitric oxide (NO x ) were measured by high-pressure liquid chromatography and chemiluminescence, respectively, from venous blood taken prior to the beginning of the arginine feeding and on the day of the study. Plasma was analyzed for agmatine by mass spectroscopy and reverse phase high-pressure liquid Figure 1 Responses to l-arginine in coronary arteries with endothelium from dogs fed a control diet or one supplemented with l-arginine for 5 weeks. Data are expressed as mean Ϯ SEM (n = 8-10 per group) of the percentage change in tension from a contraction to PGF 2␣ (2 M). Experiments were conducted in the presence of indomethacin (10 −5 M). Responses of rings without endothelium were similar to those with endothelium and are omitted for clarity. Asterisks denote responses to l-arginine in rings from control dogs that were significantly different from those of arginine-fed dogs (areas of the curves using an unpaired t-test, p Ͻ 0.001).
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Organ chamber studies
Four weeks postoperatively (after 5 weeks of arginine feeding), animals were anesthetized (sodium pentobarbital, 30 mg/kg intravenously). Hearts were removed and were placed in chilled modified Krebs-Ringer bicarbonate solution (control solution; millimolar composition: NaCl, 118.3; KCl, 4.7; MgSO 4 , 1.2; KH 2 PO 4 , 1.2; CaCl 2 , 2.5; NaHCO 3 , 25; dextrose, 11.1; and CaEDTA, 0.026). Vein grafts were removed and studied in other experiments. 26 Left circumflex coronary arteries were dissected from surrounding connective tissue and cut into at least eight rings of 4 mm in length. The endothelium was intentionally removed from some rings by gently rolling each ring across a moist surface using watch-maker forceps inserted through the lumen. Rings with and without endothelium were studied in parallel.
Rings were suspended between a fixed point and a force transducer (Gould UC2, Cleveland, OH, USA) by two stainless steel wire stirrups inserted into the lumen of the vessel. The rings were placed in organ baths filled with 25 ml control solution at 37°C and gassed with 95% O 2 and 5% CO 2 . Passive tension on each ring was progressively increased in a stepwise fashion and active tension to KCl (20 mM) was measured at each level of stretch until each ring was stretched to the optimal point of its length-tension curve. All responses of arteries from different animals were obtained from the optimal length for each individual ring.
The optimal length was recorded as resting tension. Rings were washed out at least twice with the control solution after each tension measurement.
Once optimal length (baseline tension) was determined, a maximal contraction to KCl (60 mM) was determined, and rings were washed three times with the control solution and allowed to equilibrate at optimal length for 40 min in indomethacin (10 −5 M) in the absence or presence of N Gmonomethyl-l-arginine (l-NMMA; 10 −4 M), tetraethylammonium (TEA; 10 −3 M) or a combination of l-NMMA plus TEA. Once an inhibitor was added to an organ chamber, it remained in the incubation solution for the duration of the Experiments were conducted in the presence of indomethacin (10 −5 M). Contractions to l-arginine were reduced significantly by l-NMMA and TEA in rings from control dogs. On the contrary, in arteries from arginine-fed dogs, responses to l-arginine were not altered significantly by either drug. Rings without endothelium did not show a significant difference in reactivity compared with rings with endothelium under the same conditions and are omitted for clarity. Asterisks denote a significant difference from control (analysis of variance, p Ͻ 0.05).
Vascular Medicine 1999; 4: 211-217 experiment. Cumulative concentration-response curves to the following agents were then recorded after submaximal contraction with prostaglandin F 2␣ (2 ϫ 10 −6 M): l-arginine (10 −8 to 10 −3 M), UK-14,304 (10 −9 to 10 −6 M), the calcium ionophore A23187 (10 −9 to 10 −6 M), or nitric oxide (3 ϫ 10 −9 to 10 −5 M). Responses to different amounts of agonist were obtained by cumulatively increasing the agonist concentration by half-log units. Rings were washed at least three times with the control solution and allowed to equilibrate for 30 min between each concentrationresponse curve.
Drugs
The following drugs were used (all from Sigma Chemical, St Louis, MO, USA unless otherwise noted): calcium ionophore A23187, indomethacin, l-arginine, l-NMMA, prostaglandin F 2␣ , tetraethylammonium and UK-14,304 (Pfizer Pharmaceuticals, Brooklyn, NY, USA). All concentrations refer to final molar (mol/l) concentrations of drugs in the organ bath. Drugs were prepared fresh daily. Nitric oxide was prepared by the method of Palmer et al. 27 Calculations and statistical analysis All data are expressed as mean Ϯ SEM. The n represents the number of dogs from which arteries were obtained. Relaxations are expressed as a percentage of the contraction to prostaglandin F 2␣ . The concentration of agonist producing 25-50% of the maximal relaxation (ED 25 or ED 50 ) was calculated from individual concentration-response curves and the mean of these values reported as the logarithm of the molar concentrations. Differences in relaxations among rings studied under different conditions within the control or arginine-fed groups were determined by use of a oneway analysis of variance (the area under the curves and ED 50 ). Bonferroni's post hoc analysis was used to identify significant differences among means. A Student's t-test for unpaired responses was used to compare pairs of rings from arginine-fed versus control dogs that had been studied under similar conditions. A p-value less than 0.05 was considered to be statistically significant.
Results
Plasma concentrations of l-arginine increased by 19.9% (from 141.5 Ϯ 8.1 mmol/l to 169.7 Ϯ 11.4 mmol/l; n = 6; p = 0.04) after 14 days of arginine feeding and did not increase further during the remaining 3 weeks of feeding. Plasma citrulline and ornithine did not change with arginine feeding and agmatine was not measureable. There were no significant changes in plasma concentrations of total oxidized products of nitric oxide (NO x ) with the arginine supplementation, nor were there differences at the end of the study period between plasma concentrations of NO x in control or arginine-fed animals (means 4.5 and 4.0 nmol/l, n = 6 and 5, respectively).
Contractions to both KCl and PGF 2␣ were comparable between rings with and without endothelium from control and arginine-fed dogs ( Table 1 ). Contractions to PGF 2␣ did not change significantly in a given ring throughout the experiment, nor were the contractions significantly affected by incubation of the rings with either l-NMMA (10 −4 M) or TEA (10 −5 M) (data not shown). Values are reported in grams as mean Ϯ SE. The number in parentheses represents the total number of rings studied. There were four to five rings/dog and six to seven dogs/group.
In rings contracted with PGF 2␣ , arginine did not cause a significant change in tension in rings from arginine-fed dogs but caused concentration-dependent increases in tension in rings from control dogs (Figure 1 ). Removal of the endothelium did not alter responses to arginine significantly in rings from either group (data not shown, n = 8-10).
Incubation of the rings with l-NMMA significantly reduced contractions to l-arginine in rings from control animals but not in rings from arginine-fed animals ( Figure 2 ). Incubation of the rings with L-NMMA did not affect contractions to PGF 2␣ . In rings without endothelium from both control and arginine-fed dogs, responses to l-arginine in the presence of l-NMMA were not different from those with endothelium under the same conditions.
Incubation of the rings with TEA did not significantly alter responses to l-arginine-fed dogs but significantly reduced contractions to l-arginine in rings from control animals ( Figure 2 ). TEA did not significantly affect contrac- Asterisk denotes a statistically significant difference between maximal relaxations in rings from arginine-fed compared with control animals (unpaired t-test of area under the curve, p Ͻ 0.001). The calculated concentration causing 50% of the maximal relaxation (EC 50 ) also differed significantly between the two groups (−log EC 50 = 7.1 Ϯ0.1, n = 7 for the arginine-fed group and 7.5 Ϯ 0.1 for the control group, n = 5, p Ͻ 0.05). UK-14,304 did not cause a significant change in tension in rings without endothelium (data not shown for clarity, n = 5-7 per group).
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tions to PGF 2␣ in either group. In rings with and without endothelium from either control or arginine-fed dogs, responses to l-arginine during incubation with a combination of l-NMMA plus TEA were not different from those obtained in the presence of l-NMMA alone (data not shown, n = 8-10 per group).
The ␣ 2 -adrenergic agonist UK-14,304 caused concentration-dependent decreases in tension in rings with but not in those without endothelium from both groups (Figure 3 ). Relaxations to UK-14,304 were significantly greater in rings from control dogs compared with arginine-fed dogs (Figure 3) . The calculated concentration causing 50% of the maximal response (EC 50 ) of UK-14,304 differed significantly between the two groups (arginine-fed group: −log EC 50 = 7.1 Ϯ 0.1, n = 7; control group: −log EC 50 = 7.5 Ϯ 0.1, n = 5, p Ͻ 0.05).
Incubation of the rings with l-NMMA reduced maximal relaxations to UK-14,304 significantly in rings from both control and arginine-fed dogs (Figure 4 ). TEA did not significantly affect the response to UK-14,304 in rings from control or the arginine-fed dogs. Incubation with l-NMMA plus TEA further inhibited responses obtained in the presence of l-NMMA alone only in rings from control dogs (Figure 4) .
The calcium ionophore A23187 caused comparable concentration-dependent relaxations only in rings with endothelium from both control and arginine-fed dogs ( Figure 5 ). TEA did not significantly alter relaxations to the ionophore in either group. l-NMMA significantly inhibited relaxations to the ionophore only in rings from arginine-fed dogs ( Figure 5 ). TEA in combination with l-NMMA caused a shift to the right in the response curve to A23187 only in rings from control dogs.
Relaxations of rings without endothelium to nitric oxide TEA did not significantly affect relaxations to UK-14,304 in arteries from control or arginine-fed dogs. Asterisks denote a significant reduction in relaxation in the presence of l-NMMA (Student's t-test for paired observations, p Ͻ0.05) and TEA in combination with l-NMMA. Only in rings from control dogs were relaxations inhibited more by the combination of TEA plus l-NMMA than l-NMMA alone.
were similar in rings from control and arginine-fed dogs. Maximal relaxations reached 100% of the contraction to PGF 2␣ and concentrations of nitric oxide causing 50% of the maximal response were 6.7 Ϯ 0.1 (−log of EC 50 , n = 7) for rings from the arginine-fed dogs and 6.5 Ϯ 0.3 (−log EC 50 , n =3) for rings from animals fed the control diet.
Discussion
Results of this study indicate that, in an experimental animal in the absence of elevated cholesterol, dietary supple- . Experiments were conducted in the presence of indomethacin (10 −5 M). Rings without endothelium did not relax to the calcium ionophore. There were no statistically significant differences in responses to this agonist in arteries between groups. Log EC 50 for A23187 was −8.01 Ϯ 0.2, n = 7 in the arginine-fed group, and −8.1 Ϯ 0.2, n = 5 in the control group. Asterisks signify a significant inhibition by l-NMMA of relaxations in rings from arginine-fed dogs (log EC 50 , −7.4 Ϯ 0.2, n = 7, in the presence of l-NMMA, p Ͻ 0.05) and by l-NMMA plus TEA of relaxations in rings from control dogs (log EC 50 , −7.3 Ϯ 0.2, n = 5, in the presence of inhibitors, p Ͻ 0.05).
mentation with l-arginine affects responses of unmanipulated coronary arteries by changes in at least two intracellular processes: one involving potassium channels, the other involving production of nitric oxide. A novel observation of this study is that responses to the amino acid itself were altered by arginine dietary supplementation. In vascular tissue, arginine can be metabolized by nitric oxide synthase, arginase, or arginine decarboxylase. 1, 23, [28] [29] [30] In addition, arginine may bind to potassium channels directly 25 and products of arginine decarboxylase may bind to nitric oxide synthase or bind to l-type calcium channels. 30, 31 That arginine feeding may affect potassium channels is supported by several observations. First, l-arginine caused contractions only in control arteries. This response to l-arginine was reduced by tetraethylammonium, a non-specific inhibitor of potassium channels. Alternately, although not statistically significant, there was a consistent tendency for arteries from arginine-fed dogs to contract to l-arginine when potassium channels were inhibited. In addition, endothelium-dependent relaxations to UK-14,304 were inhibited further by TEA when production of nitric oxide was inhibited by l-NMMA only in arteries from control animals. These results suggest that there may be a tonic change in activation of potassium channels associated with arginine feeding. It is unclear whether activation of potassium channels is associated directly or indirectly with production of nitric oxide because the combination of TEA plus l-NMMA caused synergistic inhibition of endotheliumdependent relaxations to both UK-14,304 and A23187 only in arteries from control dogs.
Although it was hypothesized that arginine feeding would increase production of nitric oxide, several results from this study argue against this conclusion. First, there was no consistent change in venous plasma concentrations of nitric oxide with arginine feeding over the time course of the study. This may not reflect arterial levels of nitric oxide, however. These results should be interpreted with caution because total oxidized products of nitric oxide (NO x ) were measured. These values may be influenced by dietary nitrite and nitrate, which could preclude measuring small changes due to arginine feeding. Secondly, the addition of l-NMMA to rings under basal tension did not result in a significant change in baseline tension in any group. Because such contractions to the arginine analog are usually taken as a measure of basal production of nitric oxide, 32 it is unlikely that basal production of nitric oxide was elevated in the arteries. Thirdly, contrary to the predicted hypothesis, endothelium-dependent relaxations to the ␣ 2 -adrenergic agonist were reduced with arginine feeding. Further, endothelium-dependent relaxations to the calcium ionophore were not significantly different in coronary arteries from control and arginine-fed dogs. Since the calcium ionophore releases endothelium-derived relaxing factors independent of receptors, capacity of calcium-induced release of endothelium-derived factors was the same in each group. Relaxations of the vascular smooth muscle to one metabolite of arginine, nitric oxide, were not affected by arginine feeding. Therefore, it is unlikely that differences in endothelium-dependent responses to UK-14,304 with arginine feeding are due to changes in sensitivity of the smooth muscle to released nitric oxide.
In addition to being metabolized to nitric oxide, arginine could be metabolized in other enzymes. For example, dietary arginine could be metabolized to agmatine which is an ␣ 2 -adrenergic agonist, and binds to nitric oxide synthase. [19] [20] [21] As might be predicted, consistent with the existence of this metabolite are the observations that endotheliumdependent relaxations to the ␣ 2 -adrenergic agonist UK-14,304 were reduced with arginine feeding. However, it was not possible to measure agmatine in venous plasma samples from arginine-fed dogs. This does not eliminate the possibility that agmatine may be locally produced within the vascular wall. 28, 29 Therefore, it is unclear at this time whether decreases in relaxation to UK-14,304 are due to down-regulation of ␣ 2 -adrenergic receptors due to stimulation by agmatine, changes in associated receptor-coupled intracellular mechanisms, such as release of either an endo-Vascular Medicine 1999; 4: 211-217 thelium-derived hyperpolarizing factor or endotheliumderived nitric oxide, or accumulation of another endogenous nitric oxide inhibitor, ADMA. 33 One of the limitations of the present study is that the effects of arginine feeding were studied in animals that had received simultaneous administration of a non-steroidal anti-inflammatory drug (aspirin). In order to assure the continued inhibition of cyclooxygenase, all experiments of the present study were conducted in the presence of indomethacin. Therefore, the results represent subacute inhibition of the metabolism of arachodonic acid through cyclooxygenase with arginine supplementation. However, this condition should be of interest because aspirin is typically prescribed in situations of vascular grafting or as prophylaxis against development of cardiovascular disease. Therefore, it is possible that individuals taking arginine supplementation may also be consuming aspirin.
In summary, the results of this study indicate that dietary supplementation with l-arginine in the absence of hypercholesterolemia may affect the activation of potassium channels and endothelium-dependent relaxations associated with activation of ␣ 2 -adrenergic receptors. Results also suggest that dietary supplementation with l-arginine in conjunction with aspirin therapy may not increase basal production of endothelium-derived nitric oxide in coronary arteries in the absence of overt coronary arterial disease. These results may explain in part the negative effects of arginine supplementation in control human subjects and in other experimental animals in the absence of cholesterol feeding.
